A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Inclusion Criteria: * Adult patients with advanced CTCL * Have had at least 2 systemic therapies * Must have evaluable disease * Eastern Cooperative Oncology Group performance status 0-2 * Adequate bone marrow, hepatic and renal function * At least 3 weeks from prior therapies * Not receiving topical steroids or have been on a stable dose of topical steroids for at least 2 weeks * Able to swallow capsules * At least 3 weeks from major surgery * Agree to practice effective contraception * Able to understand and willing to sign the informed consent form Exclusion Criteria: * Receiving systemic steroids * Receiving topical or systemic retinoids or vitamin A * Receiving radiotherapy, biological therapy,or any other investigational agents * Uncontrolled intercurrent illness * Pregnant or lactating women * Known to be HIV-positive * Active hepatitis B and/or hepatitis C infection